Physician profile
Ami N Fraser
NPI 1518071273
$3,704.66
in general payments reported to CMS, 2019-2025
21 companies · $656 in 2025
The $656 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $312 · 2021: $592 · 2022: $690 · 2023: $546 · 2024: $402 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $817.00 | 2022-2025 | Biotrue One Day, Infuse, Xiidra |
| Alcon Vision LLC | $627.89 | 2019-2025 | Wavelight Refractive Suite, Total30, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $569.00 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $465.56 | 2019-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $223.18 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $163.37 | 2019-2025 | |
| Oyster Point Pharma, INC. | $150.70 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $133.41 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $120.51 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $58.69 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $44.13 | 2025 | Acthar |
| Allergan, INC. | $43.68 | 2020-2021 | |
| Lombart Brothers, INC. | $43.07 | 2019 | |
| Coopervision INC. | $41.85 | 2022 | |
| Dompe US, INC. | $41.31 | 2024-2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $40.31 | 2020 | |
| Abbvie INC. | $35.67 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $29.57 | 2019-2021 | |
| Astellas Pharma US INC | $20.94 | 2024 | Izervay |
| Horizon Therapeutics Plc | $20.11 | 2023 | Tepezza |
| Lkc Technologies, INC. | $14.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.